生物瓣膜衰败后的经导管与外科再次换瓣比较
该回顾性队列研究纳入2015至2020年间在加州、纽约州和新泽西州因生物瓣主动脉瓣衰败接受瓣中瓣经导管主动脉瓣置换(ViV-TAVR)或再次外科主动脉瓣置换(redo SAVR)的1771例患者,经倾向性匹配形成375对。围术期ViV-TAVR的大出血、急性肾衰竭和新起搏器植入率更低,但5年全因死亡率更高;2年内死亡率无差异,2年后ViV-TAVR死亡和心衰住院风险显著增加。
要点
- ViV-TAVR围术期大出血、急性肾衰竭和新起搏器植入率低于redo SAVR。
- 2年内两组全因死亡率无差异,2年后ViV-TAVR死亡风险显著升高。
- ViV-TAVR组5年全因死亡率23.4%,redo SAVR组13.3%。
核心结论
- 与redo SAVR相比,ViV-TAVR围术期并发症更少且2年内全因死亡率相似。
- 但ViV-TAVR与更高的晚期死亡率和心衰住院率相关。
研究设计与样本
- 共纳入1771例患者,中位随访2.3年(IQR 1.1-4.0),倾向性匹配后形成375对。
主要发现
- 2015至2020年ViV-TAVR占比从35.3%(159/451)升至62.5%(498/797)。
- 5年全因死亡率ViV-TAVR 23.4%(95%CI 15.7-34.1) vs redo SAVR 13.3%(95%CI 9.2-18.9)。
- 2年后ViV-TAVR死亡风险更高(HR 2.97;95%CI 1.18-7.47),心衰住院风险更高(HR 3.81;95%CI 1.57-9.22)。
临床怎么用
- 对于生物瓣衰败患者,ViV-TAVR可减少围术期并发症,但需权衡2年后的晚期死亡和心衰住院风险。
- 临床决策应结合患者预期寿命和瓣膜耐久性,并强调长期随访。
局限性
- 回顾性设计可能受残余混杂影响。
- 研究结果需随机临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The use of valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) has been rapidly expanding as an alternative treatment to redo surgical aortic valve replacement (SAVR) for failed bioprosthetic valves despite limited long-term data. OBJECTIVE: To assess mortality and morbidity in patients undergoing intervention for failed bioprosthetic SAVR. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective population-based cohort analysis conducted between January 1, 2015, and December 31, 2020, with a median (IQR) follow-up time of 2.3 (1.1-4.0) years. A total of 1771 patients with a history of bioprosthetic SAVR who underwent ViV-TAVR or redo SAVR in California, New York, and New Jersey were included. Data were obtained from the California Department of Health Care Access and Information, the New York Statewide Planning and Research Cooperative System, and the New Jersey Discharge Data Collection System. Exclusion criteria included undergoing TAVR or redo SAVR within 5 years from initial SAVR, as well as infective endocarditis, concomitant surgical procedures, and out-of-state residency. Propensity matching yielded 375 patient pairs. Data were analyzed from January to December 2023. INTERVENTIONS: ViV-TAVR vs redo SAVR. MAIN OUTCOMES AND MEASUREMENTS: The primary outcome was all-cause mortality. Secondary outcomes were stroke, heart failure hospitalization, reoperation, major bleeding, acute kidney failure, new pacemaker insertion, and infective endocarditis. RESULTS: From 2015 through 2020, the proportion of patients undergoing ViV-TAVR vs redo SAVR increased from 159 of 451 (35.3%) to 498 or 797 (62.5%). Of 1771 participants, 653 (36.9%) were female, and the mean (SD) age was 74.4 (11.3) years. Periprocedural mortality and stroke rates were similar between propensity-matched groups. The ViV-TAVR group had lower periprocedural rates of major bleeding (2.4% vs 5.1%; P = .05), acute kidney failure (1.3% vs 7.2%; P < .001), and new pacemaker implantations (3.5% vs 10.9%; P < .001). The 5-year all-cause mortality rate was 23.4% (95% CI, 15.7-34.1) in the ViV-TAVR group and 13.3% (95% CI, 9.2-18.9) in the redo SAVR group. In a landmark analysis, no difference in mortality was observed up to 2 years (hazard ratio, 1.03; 95% CI, 0.59-1.78), but after 2 years, ViV-TAVR was associated with higher mortality (hazard ratio, 2.97; 95% CI, 1.18-7.47) as well as with a higher incidence of heart failure hospitalization (hazard ratio, 3.81; 95% CI, 1.57-9.22). There were no differences in 5-year incidence of stroke, reoperation, major bleeding, or infective endocarditis. CONCLUSIONS AND RELEVANCE: Compared with redo SAVR, ViV-TAVR was associated with a lower incidence of periprocedural complications and a similar incidence of all-cause mortality through 2 years' follow-up. However, ViV-TAVR was associated with higher rates of late mortality and heart failure hospitalization. These findings may be influenced by residual confounding and require adjudication in a randomized clinical trial.
引用
- Tran JH, Itagaki S, Zeng Q, et al. Transcatheter or Surgical Replacement for Failed Bioprosthetic Aortic Valves. JAMA Cardiol. 2024. PMID: 38776106. doi:10.1001/jamacardio.2024.1049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。